We describe here application of a novel bispecific antibody platform termed Dual-Affinity Re- Targeting (DART™) to Finally, the ability of the CD19xTCR DART to inhibit B-cell lymphoma in NOD/SCID mice when co-administered with human PBMC supports further evaluation of DART molecules for the treatment of B-cell malignancies.
Introduction
Targeted monoclonal antibody-based therapies provide effective and safe treatments for hematological malignancies. Rituximab, which specifically targets the B-cell antigen CD20, has provided the greatest success, revolutionizing the treatment of the two most common forms of NHL: follicular and diffuse large B-cell lymphoma. In addition, mAbbased therapies targeting CD52 (alemtuzumab) and CD33 (gemtuzumab ozogamicin) have been approved for the treatment of CLL and AML respectively. Despite the progress of these strategies, they do have limitations. Only a fraction of patients respond to rituximab and the majority of those that respond will eventually relapse. Treatment with alemtuzumab and gemtuzumab are limited by safety concerns and many additional hematological malignancies do not respond to treatment with any of these targeted therapies. Various therapies based on alternate mAbs including second generation anti-CD20 mAbs and those targeting alternate cell-surface proteins such as CD19, CD22, CD30, CD37, CD40, and CD74 have been developed and are at different stages of clinical testing in the hope of providing approaches to treat a broader spectrum of hematological malignancies that are poorly served by existing therapy 15 , 11 .
While targeting of cell surface antigens themselves can mediate anti-tumor activity through induction of apoptosis, most mAb-based activity against hematological malignancies is reliant on either Fc mediated effector functions such as CDC and ADCC 14 , 29 or is engineered through conjugation of an immunotoxin or radiolabeled isotope 15 . Considering the potential of naturally occurring cytotoxic T lymphocytes (CTL) to mediate cell lysis, various strategies have also been explored to recruit CTLs to mediate tumor cell killing. Tumor-specific CTLs exert extremely potent effects through recognition of the corresponding peptide/MHC complex recognized by their TCR, and are among the most potent cells that mediate anti-tumor effects. A major limitation in generating tumor-specific CTLs in vivo is that their induction requires the use of vaccine strategies, such as dendritic cell-based vaccines 34 , capable of breaking tolerance to cancer self antigens. As an alternative, ex-vivo expansion and activation of rare tumor specific CTLs for re-infusion into cancer patients has been employed 18 . Cancer cells however can down-regulate MHC expression as an escape mechanism, thus preventing
CTLs' ability to recognize their antigenic peptide. Genetic manipulation of patients Tcells to express chimeric antigen receptors comprising a tumor specific antigen and T- 36 , 25 . The CD19xCD3 DART was constructed using anti-CD19 Fv sequences from HD37 and anti-CD3 Fv sequences from TR66 13, 21 . CD19xCD3
BiTE was constructed using the same antibody sequences with linkers from blinatumomab/MT103 as described 13, 26 . These Fv sequences are identical to those used to construct the DART. HER2xTCR and 4420xTCR DARTs were similarly constructed using anti-HER2 sequences derived from 4D5, the murine mAb from which trastuzumab is derived 10 Human PBMC Reconstitution Xenograft Studies. 7-8 week old NOD/SCID female mice (Taconic Farm) were randomly divided into groups of 6-8, and inoculated subcutaneously (left flank) with 1x10 6 Raji cells +/-5x10 6 human PBMC in 50% matrigel.
One hour later, each mouse received test molecules or vehicle intravenously. An additional dose was administered on each of the four following days (five doses total).
Tumor dimensions were scored one week after initial administration of test molecules.
Arithmetic average of tumor dimension from each group was plotted against time. All animal studies were performed under MacroGenics Animal Care and Use Committee approval.
Results

Generation and characterization of CD19xCD3 Bispecific Antibodies
Prior studies employing various bispecific antibody based molecules have demonstrated that a broad spectrum of B-cell lymphomas can be targeted for elimination by T cells through co-engagement of CD3 on T cells and CD19 expressed on B cells 6, 16, 26 . To determine the applicability of DART molecules to support redirected T-cell killing and allow comparison to previously tested bispecific platforms, a CD19xCD3 DART was therefore constructed. The most advanced CD19xCD3 bispecific molecule in clinical development is blinatumomab; therefore a DART molecule was generated utilizing anti-CD3 and anti-CD19 variable antibody regions identical to those contained in blinatumomab (Fig 1) . To gauge the bispecific binding properties and cellular activity of the CD19xCD3 DART, a cognate CD19xCD3 single-chain BiTE molecule (i.e.
blinatumomab) was generated in parallel to serve as a reference molecule. In comparison to the BiTE, which is comprised of two single chain Fvs connected by a short linker, the DART molecule is a covalently linked bispecific diabody designed to overcome limitations of prior bispecific diabodies ( Figure 1A ) 19 . Each bispecific molecule was expressed in CHO and purified to homogeneity using antigen-affinity (sCD3) and size exclusion chromatography ( Figure 1B ). SDS-PAGE analysis under nonreducing conditions indicates that both the BiTE and DART migrate close to 50 kDa with the majority of the DART covalently linked. Under reducing conditions, the molecules migrate as anticipated with the separate DART chains co-migrating around 26 KDa while the single chain BiTE maintains migration at 50 kDa ( Fig 1C) . As an alternative strategy, BiTE was purified using metal affinity chromatography and SEC. In all assays tested, this material behaved identically to the CD3 affinity purified material (data not shown).
Both the CD19xCD3 BiTE and DART molecules exhibited dual specific binding in an ELISA format with the DART demonstrating slightly enhanced binding (Fig 1D) .
Consistent with this observation, SPR analyses revealed increase in affinity of the DART for both CD3 and CD19 compared to the BiTE (Table 1) . Equilibrium dissociation constants obtained for BiTE-hCD19 (1.3x10 -9 M) and BiTE-hCD3 (2.63x10
interactions are consistent with those published for BiTE interaction with Nalm6 and purified T-cells 1.49x10 -9 M and 2.67x10 -7 M correspondingly 13 . The approximate two fold decrease in the K D for DART interactions with corresponding antigens was mainly due to increased association rate for hCD3 binding and lower dissociation rate for hCD19
binding.
CD19xCD3 DART exhibits potent redirected killing of B-cell lymphoma
The CD19xCD3 DART was evaluated for the ability to redirect immune cell killing against CD19 expressing malignant B-cell lines using either freshly isolated human PMBC or IL-2 activated PBMC as the effector cell population. Experiments performed using multiple independent donor PBMC revealed the CD19xCD3 DART to be more potent than CD19xCD3 BiTE (representative donor data shown in Figure 2 ). With freshly isolated resting human PBMC the maximal level of cytotoxicity mediated by the DART was considerably greater than that mediated by BiTE while the concentration required to obtain 50% of maximal activity (EC50) up to 60-fold lower (Figs 2 A-B ). Analyses performed with IL2-activated human PBMC confirmed the DART to be more potent than the BiTE with 16-25x fold lower EC50, although there was less improvement in the overall level of cell lysis compared to that observed with resting PBMC (Fig 2D-E) .
Neither molecule mediated lysis of CD19 negative cell lines with either resting or activated PBMC (Fig 2) .
CD19xTCR DART displays potent B-cell lymphoma killing and T-cell activation properties similar to CD19xCD3 DART
To evaluate the flexibility of DART based molecules to redirect T-cell killing and explore the feasibility of employing an alternative T-cell antigen, DART molecules were constructed comprising T-cell binding specificity for the TCRαβ subunits of the T-cell receptor. Specifically, a humanized Fv region derived from the murine BMA031 antibody 37 , 33 that binds to an invariant region of the TCRαβ subunits of the T-cell receptor was used to engage the TCR. Two independent DART molecules were generated: CD19xTCR comprising bispecificity for CD19 and TCRαβ and 4420xTCR
comprising specificity for fluorescein and TCRαβ (Fig 3A-B) . To evaluate their cellular binding specificities the molecules were evaluated by flow cytometry for binding to Tcells and B-cells. As expected CD19xTCR exhibits specificity for both B-cells and Tcells, while the 4420xTCR DART only binds T-cells (Fig 3C) .
Evaluation of the CD19xTCR to redirect immune cell killing revealed it to have essentially overlapping potency with CD19xCD3 DART regardless of target cell population, effector cell population or E:T ratio ( Figure 4 ). With resting PBMC as the effector population, both DARTs displayed equally potent killing of Raji (Fig 4A) or Daudi cells line (supplementary data) that was greater than that mediated by the CD19xCD3
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From BiTE, based both on the maximal level of lymphoma cell lysis and EC50. The enhanced level of potency mediated by the DART on Raji cells was independent of E:T ratio (supplementary data). A similar pattern of response to the DART molecules was also observed on Raji using IL2 activated CD8 T-cells ( Fig 4B) . As anticipated, neither CD19xTCR nor CD19xCD3 based bispecific molecules mediated T-cell killing of a non CD19 expressing cell line (RPMI-8226, data not shown). Analyses of T-cell activation revealed similar responses mediated by each DART as measured by CD69 induction on either CD4 and CD8 T-cell subsets (Fig 4C-D) or IFNγ release (Fig 4E) . Consistent with the redirected killing data, the level of T-cell activation mediated by the DART molecules was greater than that observed by the BiTE. No cell killing, T-cell activation or cytokine release was observed with the 4420xTCR DART in any of the assays indicating the requirement for coligation of both TCR and CD19 to obtain cell killing.
CD19 directed DART molecules mediate autologous B-cell depletion, with T-cell activation dependent on target engagement.
Considering CD19 is expressed on normal peripheral B-cells, the ability of the DART molecules to mediate autologous B-cell depletion was evaluated on human PBMC.
Consistent with their ability to redirect killing of lymphoma cells, both the CD19xCD3 DART and CD19xTCR DART mediated essentially the same level of autologous B-cell depletion as measured by reduced levels of CD20 positive cells (Fig 5A) . The level of Bcell depletion observed with the DARTs was greater than that mediated by the BiTE based on maximal level of depletion and reduced EC50, again consistent with the enhanced activity observed by the DARTs on B-cell lymphoma. In contrast the parental TCR mAb or 4420xTCR DART (data not shown) mediated no reduction in B-cell number indicating the requirement for B-cell engagement to obtain depletion. The ability of the bispecific molecules to induce T-cell proliferation was also examined in PBMC (Fig 5B) . (Fig 6) . Clear cell-cell association was observed with both CD19 based DARTs and with the CD19 based BiTE in the presence of 10 ng/mL bispecific antibody (Fig 6A) . With the CD19xCD3 and CD19xTCR DARTs, up to 15-17% of the total cell population was observed as cell-cell associated. In contrast, only 5-6% of the mixed Jurkat/Daudi cell population was found to be associated in the presence of the CD19xCD3 BiTE (Fig 6A) . The enhanced level of cell-cell association mediated by the DARTs was observed consistently across a range in concentration of bispecific antibody ( Fig 6B) . As expected, neither CD19 mAb alone nor 4420xTCR DART mediated association of Jurkat T-cell with Daudi B-cells at any concentration tested.
CD19xTCR DART inhibits B-cell lymphoma in xenograft model.
Previously it has been demonstrated that the ability to redirect T-cell killing can also be recapitulated in xenograft models in which human PBMC are provided as an effector population 17 . These studies have included evaluation and demonstration of efficacy for CD3 based bispecific molecules. Considering we have incorporated a novel T-cell targeting specificity into the DART molecules (TCRαβ) we determined if the CD19xTCR
DART could also block human B-cell lymphoma growth in mice. Complete protection in a Raji xenograft model was observed with the CD19xTCR DART when administered at 10ug doses (Fig 7A) . Protection from tumor growth was also observed in a second study employing a lower dose (3 µg per injection) and an independent human PBMC population ( Fig 7B) . As expected, lack of activity with CD19xTCR DART (10 µg per dose) in the absence of human PBMCs reveals the need for T-cell engagement to block 
Discussion
As an initial step to evaluate the ability of DART molecules to redirect T-cell killing, activity of a CD19xCD3 DART was compared to that of a CD19xCD3 BiTE incorporating the binding specificities of blinatumomab, a molecule presently undergoing clinical evaluation 4 . As anticipated, the CD19xCD3 BiTE displayed potent activity against CD19
positive lines with EC 50 values (in the 10-100 pg/mL range) consistent with previously published reports using either resting or prestimulated effector populations 26 , 28 . The CD19xCD3 DART, however, exhibited even greater potency than the BiTE in redirected killing, based both on the maximal level of lymphoma cell lysis obtained and lower EC 50 values (Figs 2, 4) . The more potent activity exhibited by the DART was observed with either unfractionated PBMC (resting or activated) or purified T-cells (activated) as the effector populations and against both B cell lymphoma and autologous B-cells.
Furthermore, it was detected independently of E:T ratio, suggesting that the DART's more effective killing was due to better T-cell:tumor-cell engagement and not to improving the effector cell availability. Importantly, neither molecule mediated any detectable killing on CD19 negative cells, indicating the requirement for target engagement for detectable CTL activity. Considering the same specificities were employed, the enhancement observed with DART is presumably due to a platform based structural difference in the molecules that promotes higher activity. Taken together these data support our hypothesis that the DART architecture provides a stable and physiological geometry to support bispecific interactions.
Within the T cell receptor/CD3 signaling complex, the most convenient targets for mAbmediated T-cell activation are the invariant chains of the T cell receptor/CD3 signaling complex, with the CD3ε chain the most commonly targeted component, as in the case for the CD3 mAb used in this report. Monoclonal antibodies directed against a common determinant on the TCRα/β chain have also been applied and shown promise in the treatment of autoimmune disease 5 , though only anti-CD3 mAbs are currently approved or under development 12 . As TCRα/β has a somewhat more limited expression than CD3ε, and in some studies shown lower potential for side effects when targeted therapeutically 38 , it was of interest to ascertain whether redirecting killing via TCR retargeting would have similar or differential properties compared to CD3. The CD3 The ability of T cell-directed bispecific molecules to attack lymphoma cells relates to both the molecule's propensity to promote direct T cell-tumor contact and lysis as well as its ability to promote T-cell activation and expansion within the tumor environment.
Occurrence of the latter phenomenon in a target-independent fashion, however, should be limited or absent, as it relates to the propensity of producing systemic side effects, such as cytokine storm. In the presence of target cells, both CD19xTCR and CD19xCD3
DART molecules mediate T-cell expansion. Consistent with the need for target coengagement to observe killing activity, no T-cell expansion was observed when the target B-cell population was depleted. This dependence on co-engagement was also observed for the BiTE molecule, consistent with previous data demonstrating the strict requirement for T-cell activation on co-engagement of the bispecific molecule 7 .
As discussed above, both CD3-and TCR-based DART molecules were significantly more potent in redirected killing assays than the BiTE. Several factors appear to contribute to explain this enhanced potency. The modest, but reproducible improved affinity for target recognition by the DART molecules may be a contributing element. T cell activity is generally thought to be very sensitive to half-life of antigen/receptor interaction. Higher association rate can result in significant increased engagement time with a target through rapid rebinding, leading to increase of T cell cytotoxic response 2 . A remaining factor may be the difference in the ability to adopt alternative structures, i.e., the degrees of freedom of the two formats. As productive engagement is likely to require For
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